Covered recipient · General Payments record
TRISHA WISE-DRAPER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$7,777.55
11 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,710.00 | 1 |
| Food and Beverage | $586.50 | 7 |
| Travel and Lodging | $464.48 | 2 |
| Education | $16.57 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $7,445.25 | 7 |
| AVEO Pharmaceuticals, Inc. | $238.18 | 1 |
| PFIZER INC. | $77.55 | 2 |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 1 |
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TRISHA WISE-DRAPER
NPI 1306162367 · CMS profile ID 1348174
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306162367?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
11 matching records · $7,777.55 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–11 of 11.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $150.00 | 11/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048436219 | CMS |
| Merck Sharp & Dohme LLC | $6,710.00 | 11/20/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048436223 | CMS |
| Merck Sharp & Dohme LLC | $47.22 | 11/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048253601 | CMS |
| Merck Sharp & Dohme LLC | $57.91 | 11/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048253679 | CMS |
| Merck Sharp & Dohme LLC | $130.64 | 11/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048253683 | CMS |
| Merck Sharp & Dohme LLC | $35.00 | 11/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048253685 | CMS |
| Merck Sharp & Dohme LLC | $314.48 | 11/05/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048253681 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 06/12/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014971743 | CMS |
| PFIZER INC. | $41.82 | 06/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049275312 | CMS |
| PFIZER INC. | $35.73 | 06/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049317625 | CMS |
| AVEO Pharmaceuticals, Inc. | $238.18 | 06/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049066903 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,091,344.57 | 191 |
| PY2024 | Recipient | $1,142.00 | 1 |
| PY2024 | Principal investigator | $1,113,643.03 | 103 |
| PY2023 | Principal investigator | $647,553.50 | 123 |
| PY2022 | Principal investigator | $951,903.86 | 101 |
| PY2021 | Principal investigator | $1,602,672.00 | 113 |
| PY2020 | Recipient | $2,270.00 | 3 |
| PY2020 | Principal investigator | $2,351,551.68 | 45 |
| PY2019 | Principal investigator | $1,957,016.08 | 55 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
101 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $124.43 | 12/31/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 914598227 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $58,717.44 | 12/13/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 214358 | No dispute reported | 06/30/2026 | 943970999 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,394.00 | 12/13/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 0000000000000000000000000000000000000000000000000000000000000000214358 | No dispute reported | 06/30/2026 | 943971023 |
| Principal investigator 1 | Alkermes, Inc. | $6,075.00 | 12/07/2022 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | No dispute reported | 06/30/2026 | 902757721 |
| Principal investigator 1 | EMD Serono, Inc. | $76.80 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951082779 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951082783 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951082787 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951082793 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951082797 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951082803 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083239 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083245 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 12/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083249 |
| Principal investigator 1 | EMD Serono, Inc. | $628.00 | 11/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083003 |
| Principal investigator 1 | EMD Serono, Inc. | $241.40 | 11/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083117 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $58,717.44 | 10/26/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 214358 | No dispute reported | 06/30/2026 | 943970993 |
| Principal investigator 1 | PFIZER INC. | $15,875.00 | 10/22/2022 | Non-covered Recipient Entity University of Cincinnati | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT | No dispute reported | 06/30/2026 | 949798117 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,157.60 | 10/19/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 0000000000000000000000000000000000000000000000000000000000000000214358 | No dispute reported | 06/30/2026 | 943971017 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $354.90 | 09/30/2022 | Non-covered Recipient Entity UC Health System | DS8201-A-J101 | No dispute reported | 06/30/2026 | 919440261 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $58,717.44 | 09/27/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 214358 | No dispute reported | 06/30/2026 | 943971005 |
| Principal investigator 1 | Seagen Inc. | $4,750.78 | 09/27/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI MEDICAL CENTER | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | No dispute reported | 06/30/2026 | 917929695 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,986.00 | 09/26/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma | No dispute reported | 06/30/2026 | 885251213 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,950.00 | 09/19/2022 | Non-covered Recipient Entity University Of Cincinnati Medical Center | Phase II 1L Metastatic H&N Single Arm Nivo Ipi Combo - A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 933191167 |
| Principal investigator 1 | PFIZER INC. | $20,370.00 | 08/24/2022 | Non-covered Recipient Entity University of Cincinnati | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT | No dispute reported | 06/30/2026 | 949803293 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $58,717.44 | 08/09/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 214358 | No dispute reported | 06/30/2026 | 943970975 |
| Principal investigator 1 | Acerta Pharma LLC | $400.00 | 08/04/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 914602941 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $354.90 | 08/01/2022 | Non-covered Recipient Entity Uc Healthcare System | DS8201-A-J101 | No dispute reported | 06/30/2026 | 935021381 |
| Principal investigator 1 | Alkermes, Inc. | $22.30 | 07/26/2022 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | No dispute reported | 06/30/2026 | 902759891 |
| Principal investigator 1 | Alkermes, Inc. | $22.30 | 07/21/2022 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | No dispute reported | 06/30/2026 | 902759889 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $31,694.40 | 07/18/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 943971029 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,000.00 | 06/22/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 914591669 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078715 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078721 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078725 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078731 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078737 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078743 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078747 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078753 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078759 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078763 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078769 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078775 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078779 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078785 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078791 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078797 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078803 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078809 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078813 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078819 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081273 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081277 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081283 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081287 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081293 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081299 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081303 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081307 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951081313 |
| Principal investigator 1 | EMD Serono, Inc. | $962.40 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083497 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083503 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083509 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083515 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083521 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083525 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083531 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083537 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083541 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,251.44 | 04/27/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 0000000000000000000000000000000000000000000000000000000000000000214358 | No dispute reported | 06/30/2026 | 943970981 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $176,152.32 | 04/26/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 214358 | No dispute reported | 06/30/2026 | 943970969 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 04/21/2022 | Non-covered Recipient Entity UC HEALTH LLC | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | No dispute reported | 06/30/2026 | 950732865 |
| Principal investigator 1 | Genentech, Inc. | $260.00 | 04/21/2022 | Non-covered Recipient Entity UC HEALTH LLC | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | No dispute reported | 06/30/2026 | 950732871 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,440.02 | 04/13/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 0000000000000000000000000000000000000000000000000000000000000000214358 | No dispute reported | 06/30/2026 | 943971011 |
| Principal investigator 1 | EMD Serono, Inc. | $565.20 | 03/24/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080945 |
| Principal investigator 1 | EMD Serono, Inc. | $565.20 | 03/01/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080781 |
| Principal investigator 1 | Daiichi Sankyo Company LTD | $3,194.10 | 02/28/2022 | Non-covered Recipient Entity UC Health System | DS8201-A-J101 | No dispute reported | 06/30/2026 | 919439955 |
| Principal investigator 1 | AstraZeneca UK Limited | $43,089.50 | 02/24/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 914596781 |
| Principal investigator 1 | Genentech, Inc. | $819.00 | 02/10/2022 | Non-covered Recipient Entity UC HEALTH LLC | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | No dispute reported | 06/30/2026 | 950754261 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $99,997.60 | 02/07/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC | No dispute reported | 06/30/2026 | 940395583 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,460.00 | 02/03/2022 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM | An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 914599353 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,711.51 | 02/03/2022 | Non-covered Recipient Entity University Of Cincinnati | Ph I II FIH Mono Nivo Combo | No dispute reported | 06/30/2026 | 933188921 |
| Principal investigator 1 | EMD Serono, Inc. | $24,213.72 | 02/03/2022 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy & Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of Head & Neck | No dispute reported | 06/30/2026 | 951100271 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,640.00 | 01/27/2022 | Non-covered Recipient Entity University Of Cincinnati | Phase II 1L Metastatic H&N Single Arm Nivo Ipi Combo - A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 933191165 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,502.88 | 01/26/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 0000000000000000000000000000000000000000000000000000000000000000214358 | No dispute reported | 06/30/2026 | 943970963 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $97,862.40 | 01/25/2022 | Non-covered Recipient Entity UC HEALTH LABORATORY | 214358 | No dispute reported | 06/30/2026 | 943970987 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078681 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078687 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078691 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078695 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078701 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078705 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951078709 |
| Principal investigator 1 | EMD Serono, Inc. | $628.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080013 |
| Principal investigator 1 | EMD Serono, Inc. | $628.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080017 |
| Principal investigator 1 | EMD Serono, Inc. | $580.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080023 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080029 |
| Principal investigator 1 | EMD Serono, Inc. | $948.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951080035 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083821 |
| Principal investigator 1 | EMD Serono, Inc. | $1,008.00 | 01/13/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies | No dispute reported | 06/30/2026 | 951083825 |
| Principal investigator 1 | Eli Lilly and Company | $50,985.00 | 01/04/2022 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | No dispute reported | 06/30/2026 | 917840683 |